Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | HNF4A | P41235 | 1/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884545 | 0.91 | KDM4E (0.52) | EGFRNR4A2MAPTKDM4ELMNA | |
| SCHEMBL9150203 | 0.88 | RXRB (0.57) | EGFRNR4A2MAPTKDM4EHPGD | |
| SCHEMBL28675075 | 0.86 | CA12 (0.56) | EGFRNR4A2MAPTKDM4ELMNA | |
| SCHEMBL7671667 | 0.86 | NR4A2 (0.56) | EGFRNR4A2MEN1MAPTKMT2A | |
| SCHEMBL70440 | 0.86 | NR4A2 (0.59) | EGFRNR4A2MEN1MAPTKMT2A | |
| SCHEMBL14252250 | 0.86 | NR4A2 (0.59) | EGFRNR4A2MEN1MAPTKMT2A | |
| SCHEMBL6889135 | 0.85 | HSD17B1 (0.54) | EGFRNR4A2MEN1MAPTKMT2A | |
| SCHEMBL12534220 | 0.85 | MAPT (0.57) | NR4A2MEN1MAPTKMT2AKDM4E | |
| SCHEMBL1761310 | 0.85 | GAA (0.56) | EGFRNR4A2MEN1MAPTKMT2A | |
| SCHEMBL30930671 | 0.84 | AXL (0.53) | EGFRNR4A2MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029148-A | N-phenyl-3- (2, 5-dioxopyrrolidin-1-yl) propionamide derivatives and similar compounds as DUX4 inhibitors for the treatment of, for example, neuromuscular diseases | 阿勒泰治疗公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20190161429-A1 | Aromatic Esters and Polyesters, Production Without Esterification Catalyst, and Use | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-05-30 | — | — | US | disclosed |
| EP-3475255-A1 | AROMATIC ESTERS AND POLYESTERS, PRODUCTION WITHOUT ESTERIFICATION CATALYST, AND USE | ExxonMobil Chemical Patents Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017222692-A1 | AROMATIC ESTERS AND POLYESTERS, PRODUCTION WITHOUT ESTERIFICATION CATALYST, AND USE | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161429-A1 | Aromatic Esters and Polyesters, Production Without Esterification Catalyst, and Use | PAH, ALKBH3, ALK | EGFR 1434/4885NR4A2 1692/4885MEN1 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.